Steve Clark

Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.
Stellar Biotechnologies Inc (NASDAQ:SBOT)

Shares of Stellar Biotechnologies Inc (NASDAQ:SBOT) Have Wild Ride

Stellar Biotechnologies Inc (NASDAQ:SBOT)

Stellar Biotechnologies Inc (NASDAQ:SBOT) failed, on heavy volume, to rise above the $1.38 high reached on October 13. SBOT stock jumped in the morning from an open at $1.15 but after 90 minutes sellers jumped in and pushed the shares back down to $1.22. There have been no news items coming across the wires that may have explained the early jump in price.

Stellar Biotechnologies Inc (NASDAQ:SBOT)

Port Hueneme, CA-based Stellar Biotechnologies Inc (NASDAQ:SBOT) has a market capitalization of less than $12 million and a stock float under eight million. The global biotechnology firm specializes in aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein. KLH is an immune-stimulating protein used for generation of antibody and cell-mediated immune responses against disease indications such as cancer and immune disorders. It provides its products under the Stellar KLH brand name.

Sales have been increasing for the past three years. In 2014, sales were posted at $400,000 and in 2016 the figure was an impressive $1.3 million. However, share dilution has been plaguing investors. In 2014, there were 7.58 million shares outstanding and that number grew to 8.83 million by 2016. Also of concern is the lack of profit – losses have been posted by Stellar Biotechnologies Inc (NASDAQ:SBOT) since 2012. For 2016 the per share loss was (-$0.57), a worse loss than the (-$0.36) shareholders experienced in 2015.

SBOT Stock

Zack’s investor Services covers SBOT stock and assigns the shares a rating of “Strong Buy”. However SBOT stock has lost over 46% for the past year, and is down over 17% for the quarter. Still, as of this writing (1 PM EST), shares are up almost 7% for the day. A casual review of a SBOT daily stock chart shows that for the past couple of months, SBOT shares have hit significant support at $1.10.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SBOT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Neothetics Inc (NASDAQ:NEOT)

Neothetics Inc (NASDAQ:NEOT) Announces Merger

Neothetics Inc (NASDAQ:NEOT)

Neothetics Inc (NASDAQ:NEOT) shares jumped after they announced entering into a merger agreement with Evofem Biosciences. Evofem, a privately held company, will merge with a wholly-owned subsidiary of Neothetics in an all-stock transaction. Neothetics will become Evofem Biosciences, Inc., and Evofem Biosciences’ Chief Executive Officer, Saundra Pelletier, will assume its leadership. Additionally, as part of the deal, Invesco Asset Management Ltd., will purchase $20 million of Evofem Biosciences’ common stock after the deal is closed.

Saundra Pelletier, Chief Executive Officer of Evofem Biosciences stated in a press release “This merger and concurrent financing provides continued funding for Evofem Biosciences’ ongoing Phase III study of Amphora® as a vaginal contraceptive – AMPOWER.  We expect to close the study database and file for FDA review in the second quarter of 2019. In addition, we have expanded our Amphora® clinical development platform with potential supplemental indications which would further strengthen its position as a cornerstone therapy in hormone-free birth control and as a preventative option for certain sexually transmitted infections.”

NEOT Stock Action

The exchange ratio, prior to the Invesco purchase of shares, is being determined by$171,400,000 Neothetics common stock being issued to the Evofem Biosciences stockholders. $28,600,000 of common stock will be retained by the Neothetics stockholders. Neothetics stockholders will own approximately 13% of the combined company and Evofem Biosciences stockholders will own approximately 87%.

Shares of Neothetics Inc (NASDAQ:NEOT) closed Monday at $0.52 and opened this morning at $0.84 before hitting a high of $1.99. By the end of the day NEOT stock closed at $1.72 on volume over 70 times the average.

Neothetics Inc (NASDAQ:NEOT) has no sales reported over the last four years. Earnings have been negative. On a per share basis, NEOT shareholders lost (-$0.94) last year. However, that was the smallest loss in the past three years for the company.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $NEOT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Celsion Corporation (NASDAQ:CLSN)

Celsion Corporation (NASDAQ:CLSN) Struggles To Close Above $6

Celsion Corporation (NASDAQ:CLSN)

Celsion Corporation (NASDAQ:CLSN) shares fell 1.69% after initially rising by 8% in pre-market trading, after the company announced the publication of a manuscript for its Phase III HEAT study, assessing ThermoDox in hepatocellular carcinoma (HCC). The article details findings from a study of 701 patients as well as results from computer simulation studies.

ThermoDox Development

ThermoDox is Celsion’s most advanced tumor-targeting drug delivery technology and employs a novel heat-sensitive liposome to address difficult-to-treat cancers. The program is currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer.

“We believe strongly that ThermoDox® may be an important new approach for the treatment of HCC. We are now fully committed to the OPTIMA Study and to learning more about how this combination therapy of standardized RFA plus ThermoDox® may significantly prolong the survival of, if not cure, patients,” said CEO Michael H. Trading.

Celsion Corporation (NASDAQ:CLSN)’s upside run, that began early in the month, is losing its momentum. The stock has struggled to close above the $6 a share on two attempts. Selling pressure appears to be slowly building. The stock has underperformed the industry for the better part of the year and the stock continues to trade at levels last seen in January.

The stock is currently rated as a ‘strong buy’ by two firms and as a ‘hold’ by one firm according to data compiled by Zack Investment Research.

Celsion’s New Financing

Celsion Corporation (NASDAQ:CLSN)

Separately, Celsion Corporation (NASDAQ:CLSN) has entered into Exercise agreements with holders of existing warrants issued in July. Pursuant to the agreement, the company has agreed to issue 2.4 million Series AAA Warrants at an exercise price of $2.07 a share and series BBB Warrants are an exercise price of $4.75 a share.

Celsion Corporation (NASDAQ:CLSN) expects gross proceeds of $15.6 million from the exercise of the Series AAA and Series BBB Warrants. Net proceeds are to be used for general corporate purposes. According to CEO, Michael Trading, the exercise agreements eliminate financial challenges that the company has faced in recent years. The executive also expects the new financing to help accelerate the development of drug candidates in the company’s pipeline.

“This significant capital infusion from the exercise of existing outstanding warrants at their original exercise prices is an example of our strategic approach to financing and is expected to extend the Company’s operating horizon through full patient enrollment of our Phase III OPTIMA Study,” said Mr.  Tardugno.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CLSN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Pareteum Corp (NYSEAMERICAN:TEUM)

Pareteum Corp (NYSEAMERICAN:TEUM) and Artilium Ink Deal

Pareteum Corp (NYSEAMERICAN:TEUM)

Pareteum Corp (NYSEAMERICAN:TEUM) traded lower after announcing the formation of a strategic partnership with London-based Mobile Virtual Network Enabler, Artilium. Shares of the company fell 5% to end Monday’s trading session at $1.14 a share.

TEUM Stock Performance

Monday’s sell-off capped yet another poor run, for a stock that has been under pressure for the better of the year. The stock is already down by more than 50% for the year as it continues to trade in a strong downtrend. The stock is at risk of plunging to multi-year lows as it continues to trade at a key support level.

The formation of a joint venture with Artilium, a provider of innovative telecommunications software solutions, is part of an effort that seeks to expand Pareteum Corporation’s footprint into new markets. Pursuant to the agreement, the two companies are to join forces in the development of new products and services.

Pareteum Merger Synergies

The global collaboration will also lead to enhanced sales coverage for both companies while increasing the speed at which new products come to market. The joint venture seeks to pursue mature markets as well as high growth underserved developing markets.

Asia and Africa are some of the markets that Artilium and Pareteum Corp (NYSEAMERICAN:TEUM) have set their eyes on. They are poised to execute plans that could produce an annual growth rate of 23% through 2021.

Pareteum’s Global Mobility Cloud Platform, when combined with Artilium One APP complementary data center infrastructure, should enable carriers and enterprises to have a complete network solution from retail to network. The merger should also enhance Pareteum’s philosophy of connecting any device on any network, anywhere.

‘Pareteum’s and Artilium are a natural fit to build a joint-solution. We are combining Pareteum’s recent success in the IoT and API economy and our deep roots in the network MVNE market, with Artilium’s robust retail, enterprise, e-commerce, and converged app platforms to create a winning combination,” stated Hal Turner, Executive Chairman of Pareteum.

TEUM Share Exchange Agreement

In addition to the formation of a joint venture, the two companies have entered into a share exchange agreement. Pursuant to the agreement Artilium is to issue 27, 695, 177 ordinary shares of 5 pence each at a notional price of 11 pence each. Pareteum Corp (NYSEAMERICAN:TEUM) in return will issue 3.2 million common shares. The New Ordinary shares and the New Common share will be subject to a 9-month lock-in-period.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $TEUM and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

WPCS International Incorporated (NASDAQ:WPCS)

WPCS International Incorporated (NASDAQ:WPCS) Shares Find Gravity

WPCS International Incorporated (NASDAQ:WPCS)

Shares of WPCS International Incorporated (NASDAQ:WPCS) are down 11.5% and trading around $1.84 just days after hitting their 52-week high of $3.38. WPCS share volume is heavy and over three times the number of shares have exchanged hands so far today versus the posted average. Interestingly, no real news has surfaced on the company since it released an earnings report on Septmeber 13, 2017.

WPCS International Incorporated (NASDAQ:WPCS)

Suisun City, CA-based WPCS International Incorporated (NASDAQ:WPCS) provides low voltage communication infrastructure services For enterprises in the North American public services, healthcare, energy, and education markets. The company installs and services voice and data networks, security systems, audio-visual solutions, and distributed antenna systems. WPCS was formerly known as Internet International Communications Ltd. and changed its name to WPCS International Incorporated in December 2004.

WPCS Sales and Earnings

Reported sales for WPCS International Incorporated (NASDAQ:WPCS) have been erratic. In 2013 the company posted a figure of $24.8 million, followed by annual sales of $15.8 million, $24.4 million, $14.6 million, and $16.7 million for 2017. However, earnings have been trending favorably. In 2013, the per share loss was (-$119.05), followed by (-$41.99), (-$-13.71), (-$3.99), and, for 2017, (-$0.76).

WPCS Stock

The per share loss contraction over the past few years is encouraging especially when viewed in the context of the increasing number of outstanding shares which carries a dilutive effect. In 2013 there were 50,000 outstanding shares. Over the years the number of outstanding shares has increased and was listed at 2.97 million for 2017. A search revealed that no investment firms have issues a stock rating on WPCS shares recently.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $WPCS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Tandem Diabetes Care Inc. (NASDAQ:TNDM)

Tandem Diabetes Care Inc. (NASDAQ:TNDM) Falls

Tandem Diabetes Care Inc. (NASDAQ:TNDM)

Tandem Diabetes Care Inc. (NASDAQ:TNDM) felt the wrath of Wall Street after announcing the pricing of an underwritten offering of shares of its common stock. Shares of the company fell 36.11% to end up at multi-year lows of $2.99 a share.

Friday’s sell-off capped yet another poor run in the stock’s performance this year. Tandem Diabetes Care Inc. (NASDAQ:TNDM) is down by more than 80% for the year as it continues to trade in a strong downtrend. Concerns about the company’s financial health remains a point of concern among investors.

Tandem Diabetes Care Inc. (NASDAQ:TNDM)

The medical device company and manufacturer of the only touchscreen insulin pumps plans to raise additional capital through the issuance of 4.6 million shares of common stock priced at $3.50 a share. The company is also offering Series A warrants for the purchase of 4.6 million shares and Series B warrants for the purchase of 4.6 million shares.

Tandem Diabetes expects gross proceeds of $16.2 million from the public offering. The company intends to use net proceeds from the offering for working capital among other general corporate purposes.

Reverse Stock-Split

The pricing of the public offering comes just days after a special meeting of shareholders approved a reverse stock split of the company’s issued and outstanding shares of common stock. The approval paves way for Tandem Diabetes Care Inc. (NASDAQ:TNDM) to initiate a split ratio of not less than 1-fo-8 and not greater than 1-for-12.

Completion of the reverse stock split will result in shares of common stock remaining at 100 million shares.

“The implementation of this reverse stock split will provide us with flexibility in our capital structure to pursue financing alternatives in support of our business plan and to bring new innovations to people with diabetes,” said Kim Blickenstaff, President, and CEO of Tandem Diabetes Care.

Insulin Pump Approval

The pricing of the public offering follows FDA approval of the company’s fifth insulin pump in five years. The company is to begin commercial launch of t: slim X2 Insulin Pump, which is the first sensor-augmented insulin pump that lets users make treatment decisions without pricking their fingers.

The new insulin pump is also the only one in the market capable of conveniently displaying user’s insulin delivery activity and Dexcom G5 Mobile CGM data on a single device.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $TNDM Symbol and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Net Element International Inc (NASDAQ:NETE)

Short-Sellers Piling into Net Element International Inc (NASDAQ:NETE)

Net Element International Inc (NASDAQ:NETE)

Net Element International Inc (NASDAQ:NETE) shares were up almost 30% after the technology company reported significant progress in its North America Transactions Solutions Segment division. Total e-commerce volumes for the first half of 2017 increased by 33% from the first half of 2016. Transactions processed for the first half of 2017 increased by 34% over the same period in 2016. New e-commerce merchants for the first half of 2017 increased by 37% over the same period in 2016.

NETE Stock

Net Element International Inc (NASDAQ:NETE)

NETE shares closed at $4.06 on Thursday and opened at $4.10 on Friday before hitting an inter-day high of $7.43 on a volume of 4.5 million shares traded. Before yesterday, NETE stock had a 30-day, daily average volume of just 193,000. While the stock hit a price almost 50% higher than its closing price, the stock is still well under its 52-week high of $15.40. Short-sellers are a significant concern for investors. Almost 85% of the outstanding shares are being held by short-sellers. Many have held the short position since late September when NETE shares were trading near $11.

However, the short-sellers could be fighting a challenging battle. Net Element International Inc (NASDAQ:NETE) has posted impressive sales increases each year since 2012 when they posted a figure of $1.4 million. By 2016, that sales figure had improved to $54.3 million. On the other hand, the company has needed to raise funds and has not been shy about conducting share offerings that dilute shareholder value. There were 210,000 outstanding shares in 2012. That number ballooned to 1.31 million by the end of 2016, and the figure is reportedly 1.71 million as of this writing.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $NETE and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

xG Technology Inc. (NASDAQ:XGTI)

xG Technology Inc. (NASDAQ:XGTI) Receives Eye-Popping Order

xG Technology Inc. (NASDAQ:XGTI)

xG Technology Inc. (NASDAQ:XGTI) shares fell 3.80% after the leading provider of wireless video solutions for law enforcement and defense markets announced a new order for its Vislink business. The new order, worth $535,000, from NEP UK, is for the company’s latest Vislink HEVC 4K capable HCAM Wireless Camera systems.

$2 Million Pre-orders

The Focal Point Camera Control systems are to be used at the 2018 Winter Olympics in South Korea. The HCAM system represents the next generation of 4K UHD wireless transmitters which is capable of supporting premium live broadcast events.

“This commitment from NEP further solidifies our relationship, and continues to highlight the market confidence in the HCAM with pre-orders now over $2 million,” said James Walton, president of IMT, Ltd.

xG Technology Inc. (NASDAQ:XGTI) market consolidation continued in Wednesday’s trading session. While the stock is up by more than 10% for the year, it continues to trade in a range after dropping from $2.50 – recorded in July.

xG Technology Inc. (NASDAQ:XGTI)

MicroLite 2 HD Launch

Separately, xG Technology Inc. (NASDAQ:XGTI), through its business unit IMT Vislink, has introduced a compelling solution for capturing real-time, high quality on camera video for electronic newsgathering. MicroLite 2 HD is the new ultra-compact COFDM wireless video transmitter designed to provide enhanced performance and video quality at a competitive price point.

The video transmission system can deliver up to 250Mw of power and provides low range, reliable HD transmission. A key advantage of MicroLite compared to other solutions in the market is its ability to operate at low latency levels and so is well suited for live sports broadcasts and video assists applications.

“With the MicroLite 2, broadcast professionals are able to transmit high definition video within a small form factor, while utilizing its lightweight design for Steadicam operations, event coverage, confidence monitoring, web content programming, rental houses and drone use,” said John Payne IV president of IMT USA.

In addition, xG Technology Inc. (NASDAQ:XGTI) has confirmed the appointment of Eric Haney as the new Regional Sales Manager focusing on unmanned systems across all markets throughout North America. According to Mr. Payne, his expertise will be invaluable in identifying business opportunities with the government, military as well as on commercial applications where the systems can be used to deliver considerable advantages.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $XGIT Symbol and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) To Unveil New Features

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) gained 5.93% after the exoskeleton technology company said it will showcase new features for its EksoGT wearable exoskeleton at an event in Denver. The company plans to showcase how its SmartAssist and EksoPulse can be used to provide personalized patient care at the 2017 American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly.

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

EKSO Stock Catalyst

During the event slated for October 12-15, 2017, the exoskeleton company will demonstrate how the FDA cleared exoskeleton can be used for stroke and spinal cord rehabilitation. Clinicians will be given an opportunity to explore the technology first hand and learn more about its clinical benefits.

The event presents an opportunity for Ekso Bionics to market its exoskeleton in a bid to strengthen investors’ confidence for its long-term prospects. The company needs a catalyst to bounce back from current trading levels after dropping to multi-year lows.

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) is down by more than 60% for the year, and is underperforming the overall industry. The stock is currently trading in a strong downtrend and at risk of dropping below $1, the minimum requirement needed for continued listing on the NASDAQ.

According to data compiled Zack Investment Research, Ekso stock is currently rated as a ‘strong buy’ by three investment firms, ‘hold’ by eight and ‘sell’ by 2.

The EksoGT exoskeleton could be the catalyst to bolster investor confidence. The device is designed to enable individuals to stand up and walk with a full weight bearing reciprocal gait. The SmartAssist technology, on the other hand, is a next-generation gait therapy software that enables personalized therapy.

Ekso Bionics’ Capital Raise

Separately, Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) has announced the results of a previously announced rights offerings. The company says it generated gross proceeds of $34 million from the offering including an investment of $20.5 million from Puissance Capital Management.

“The capital raised through this financing will provide us with additional resources to further advance the adoption and development of our innovative exoskeleton solutions in both the rehabilitation and industrial verticals. We are pleased to have Puissance Capital as a new investor as they share our vision for innovating products,” said CEO, Thomas Looby.

In addition, Ekso Bionics has confirmed the appointment of Ted Wang into its board of directors. He joins the company with a strong track record of successful, strategic and financial management. He also boasts deep knowledge of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)’s technology, products and end markets.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $EKSO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Yawns Greet Gevo, Inc. (NASDAQ:GEVO) News

Gevo, Inc. (NASDAQ:GEVO)

Gevo, Inc. (NASDAQ:GEVO) shares gained 0.71% after the renewable energy technology company announced it will partner Los Alamos National Laboratory (LANL) to improve the energy density of some of its hydrocarbon products. The two are also to share ideas on ways to fine tune the composition of the catalysts used in Gevo’s proprietary ETO process.

GEVO Stock Performance

Shares of Gevo continue to trade in a downtrend despite the signing an agreement with LANL. The company faces an uncertain future especially on the stock dropping below $1, a minimum requirement for continued listing in the NASDAQ.

Gevo, Inc. (NASDAQ:GEVO) has been under pressure since the start of the year as seen by the stock losing more than 80% in market value. Investor confidence on the stock is at all-time low. Industry observers are keenly waiting to see if the LANL deal is the catalyst that will help breathe life into the stock.

Gevo, Inc. (NASDAQ:GEVO)

LANL – GEVO Collaboration

LANL and GEVO are planning to develop a low-cost catalytic technology that is to be integrated into an existing isobutanol-to-hydrocarbons process that reportedly produces high-energy density fuels. HEDFs are currently being used by the U.S military in air and sea-launched cruise missiles.

“Currently, certain HEDFs are supplied by limited suppliers, so the DOD is interested in supporting alternative sources of these fuels, and potentially at a lower cost. The added benefit that this would be a renewable fuel that helps reduce greenhouse gas emissions is just icing on the cake,” said Dr. Patrick Gruber, Gevo’s Chief Executive Officer.

ATJ – Virgin Airlines Deal

Separately, Gevo, Inc. (NASDAQ:GEVO) has inked a deal that paves way for it to start supplying its renewable alcohol-to-jet fuel (ATJ) to the Virgin Australia Group. The airline will be responsible for coordinating purchase, supply, and blending of ATJ into the fuel system at the Brisbane Airport. The Queensland government has already echoed its support for the arrangement which it says is the first step in the development of renewable jet fuel.

Gevo, Inc. (NASDAQ:GEVO) is to supply the ATJ from its hydrocarbon plant in Texas. The company plans to expand its production capabilities at the Luverne Facility to meet the growing demand. Plans are also underway to obtain binding supply contracts for a combination of isobutanol and hydrocarbon products, which should be equal to the expected capacity increase.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $GEVO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.